Menu
Search
|

Menu

Close
X

Genomic Health Inc GHDX.OQ (NASDAQ Stock Exchange Global Select Market)

57.34 USD
-0.97 (-1.66%)
As of Jul 21
chart
Previous Close 58.31
Open 58.25
Volume 117,061
3m Avg Volume 88,148
Today’s High 58.36
Today’s Low 56.27
52 Week High 58.83
52 Week Low 26.54
Shares Outstanding (mil) 34.65
Market Capitalization (mil) 1,144.69
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
3.00 Mean rating from 9 analysts

KEY STATS

Revenue (mm, USD)
FY18
93
FY17
341
FY16
328
FY15
287
EPS (USD)
FY18
-0.107
FY17
-0.113
FY16
-0.421
FY15
-1.030
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.76
Price to Sales (TTM)
vs sector
3.42
5.73
Price to Book (MRQ)
vs sector
6.53
5.47
Price to Cash Flow (TTM)
vs sector
229.44
23.29
Total Debt to Equity (MRQ)
vs sector
0.00
16.84
LT Debt to Equity (MRQ)
vs sector
0.00
12.51
Return on Investment (TTM)
vs sector
-3.19
14.61
Return on Equity (TTM)
vs sector
-3.25
16.34

EXECUTIVE LEADERSHIP

Kimberly Popovits
Chairman of the Board, President, Chief Executive Officer, Since 2012
Salary: $686,400.00
Bonus: $642,470.00
Gordon Cole
Chief Financial Officer, Chief Operating Officer, Since 2016
Salary: $520,000.00
Bonus: $297,440.00
Steven Shak
Chief Scientific Officer, Since 2014
Salary: $489,300.00
Bonus: $279,880.00
Phillip Febbo
Chief Medical Officer, Since 2013
Salary: --
Bonus: --
Laura Kammeyer
Chief Communications Officer, Since 2014
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

301 Penobscot Dr
REDWOOD CITY   CA   94063-4700

Phone: +1650.5569300

Genomic Health, Inc. is a healthcare company that provides genomic-based diagnostic tests to personalize cancer treatment. The Company develops and commercializes genomic-based clinical laboratory services. The Company's Oncotype IQ Genomic Intelligence Platform is consisted of its flagship line of Oncotype DX gene expression tests, as well as its Oncotype SEQ Liquid Select test. Its research and development activities are focused on developing a pipeline of tests to optimize the treatment of various cancers including breast, colon, prostate and other cancers. It offers its Oncotype DX tests as a clinical laboratory service, where it analyzes the expression levels of genes in tumor tissue samples and provides physicians with a quantitative gene expression profile expressed as a single quantitative score, which it calls a Recurrence Score for invasive breast cancer and colon cancer, a DCIS Score for ductal carcinoma in situ (DCIS), and a Genomic Prostate Score, for prostate cancer.

SPONSORED STORIES